Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT03214393
• Date of registration: 10/07/2017
• Prospective Registration: Yes
• Primary sponsor: Cairo University
• Public title: Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy
• Scientific title: Role of Maternal Anticardiolipin and Anti-B2 Glycoprotein I Antibodies in Correlation With Fetal Doppler in Prediction of Adverse Pregnancy Outcome in Patients With Preeclampsia
• Date of first enrolment: August 1, 2017
• Target sample size: 100
• Recruitment status: Not yet recruiting
• URL: https://clinicaltrials.gov/show/NCT03214393
• Study type: Observational
• Phase: N/A

Countries of recruitment

Egypt

Contacts

• Name: Doaa Belal, MD

• Name: Doaa Sh Belal, MD

• Name: Doaa Sh Belal, MD
• Affiliation: Cairo U

Key inclusion & exclusion criteria

Inclusion Criteria:

- Pregnant women 32 weeks or more gestational age

- Pre-eclampsia

- Singleton pregnancy

Exclusion Criteria:

- Intrauterine fetal death

- Fetus with apparent congenital anomalies

- Pregnant females with other medical disorders

- History of essential hypertension.

- History of antepartum hemorrhage.

- History of rupture of membranes.



Age minimum: 18 Years
Age maximum: N/A
Gender: Female

Health Condition(s) or Problem(s) studied

Pre-Eclampsia

Intervention(s)

Diagnostic Test: Doppler

Diagnostic Test: serum antibodies

Primary Outcome(s)

percentage of cases that develop severe pre-eclampsia [Time Frame: It will be calculated after 1 year from the start of the study]

Secondary ID(s)

3650

Source(s) of Monetary Support

Please refer to primary and secondary sponsors